EQL Pharma has today received market approval for its melatonin tablets 0.5mg, 1mg, 2mg, 3mg, 4mg, 5mg in Denmark and Norway. The brand will, just like in Sweden, be "Mellozzan" in Denmark, but will be sold in Norway under the brand "Mallozen".
 

EQL's melatonin is a prescription drug used to treat insomnia in children 6 - 17 years with ADHD where other sleep support measures are not sufficient. It can also be taken by adults to treat the effects of jet lag for a short time.
 

The Norwegian market currently has two registered competitors, one of which with only the jet lag indication, and sales of approximately 56mNOK with an annual growth of approximately 40%. The Danish market has three registered competitors, two of which have only the jet lag indication. Sales in Denmark are about 33mDKK with an annual growth of about 55%.

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 - 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 17 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 10 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.

https://news.cision.com/eql-pharma/r/eql-pharma-s-melatonin-tablets-approved-in-denmark-and-norway,c3519171

https://mb.cision.com/Main/11664/3519171/1544532.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English